A
Andrew J. Olaharski
Researcher at Agios Pharmaceuticals
Publications - 29
Citations - 1166
Andrew J. Olaharski is an academic researcher from Agios Pharmaceuticals. The author has contributed to research in topics: Genotoxicity & Micronucleus test. The author has an hindex of 14, co-authored 27 publications receiving 1008 citations. Previous affiliations of Andrew J. Olaharski include Hoffmann-La Roche & University of California, Berkeley.
Papers
More filters
Journal ArticleDOI
Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers
Janeta Popovici-Muller,Lemieux Rene M,Erin Artin,Jeffrey O. Saunders,Francesco G. Salituro,Jeremy Travins,Giovanni Cianchetta,Zhenwei Cai,Ding Zhou,Cui Dawei,Ping Chen,Kimberly Straley,Erica Tobin,Fang Wang,Muriel D. David,Virginie Penard-Lacronique,Cyril Quivoron,Véronique Saada,Stéphane de Botton,Stefan Gross,Lenny Dang,Hua Yang,Luke Utley,Yue Chen,Hyeryun Kim,Shengfang Jin,Zhiwei Gu,Gui Yao,Zhiyong Luo,Xiaobing Lv,Cheng Fang,Liping Yan,Andrew J. Olaharski,Lee Silverman,Scott A. Biller,Shinsan M. Su,Katharine E. Yen +36 more
TL;DR: AG-120 (ivosidenib), an inhibitor of the IDH1 mutant enzyme that exhibits profound 2-HG lowering in tumor models and the ability to effect differentiation of primary patient AML samples ex vivo is reported.
Journal ArticleDOI
Tetraploidy and chromosomal instability are early events during cervical carcinogenesis.
Andrew J. Olaharski,Rita Sotelo,Gilberto Solorza-Luna,María E. Gonsebatt,Patricia Guzman,Alejandro Mohar,David A. Eastmond +6 more
TL;DR: Tetraploidsy and chromosomal instability are related events occurring during the early stages of cervical carcinogenesis that predispose cervical cells to the formation of aneuploidy frequently involving the loss of Chromosome 17.
Journal ArticleDOI
Leucine-Rich Repeat Kinase 2 (LRRK2)-Deficient Rats Exhibit Renal Tubule Injury and Perturbations in Metabolic and Immunological Homeostasis
Daniel Ness,Zhao Ren,Shyra J. Gardai,Douglas Sharpnack,Victor J. Johnson,Richard J. Brennan,Elizabeth F. Brigham,Andrew J. Olaharski +7 more
TL;DR: The phenotype of the L RRK2 null rat is suggestive of a complex biology influencing metabolism, immune function and kidney homeostasis, and Ontological pathway analysis of LRRK2 across metabolic and kidney processes and pathological categories suggested that the thioredoxin network may play a role in perturbing these organ systems.
Journal ArticleDOI
Interlaboratory evaluation of genomic signatures for predicting carcinogenicity in the rat.
Mark R. Fielden,Alex Nie,Michael K. McMillian,Chandi S. Elangbam,Bruce A. Trela,Yang Yang,Robert T. Dunn,Yvonne P. Dragan,Ronny Fransson-Stehen,Matthew S. Bogdanffy,Stephen P. Adams,William R. Foster,Shen-Jue Chen,Phil Rossi,Peter Kasper,David Jacobson-Kram,Kay S. Tatsuoka,Patrick J. Wier,Jeremy Gollub,Donald N. Halbert,Alan H. Roter,Jamie K. Young,Joseph F. Sina,Jennifer Marlowe,Hans-Joerg Martus,Jiri Aubrecht,Andrew J. Olaharski,Nigel Roome,Paul Nioi,Ingrid D. R. Pardo,Ron Snyder,Richard Perry,Peter Lord,William B. Mattes,Bruce D. Car +34 more
TL;DR: The Carcinogenicity Working Group of the Predictive Safety Testing Consortium has concentrated on sharing data to test the predictivity of two published hepatic gene expression signatures, including the signature by Fielden et al. (2007), which proved to be relatively robust and more accurate than expected by chance.
Journal ArticleDOI
The flavoring agent dihydrocoumarin reverses epigenetic silencing and inhibits sirtuin deacetylases.
Andrew J. Olaharski,Jasper Rine,Brett Marshall,Brett Marshall,Joshua E. Babiarz,Luoping Zhang,Eric Verdin,Eric Verdin,Martyn T. Smith +8 more
TL;DR: Dihydrocoumarin (DHC), a compound found in Melilotus officinalis (sweet clover) that is commonly added to food and cosmetics, disrupted heterochromatic silencing and inhibited yeast Sir2p as well as human SIRT1 deacetylase activity and increased p53 acetylation and apoptosis, a phenotype associated with senescence and aging.